OnCo
peoplePerson

Benjamin Solomon

Principal investigator of CROWN, where lorlatinib produced the longest disease control ever recorded for a targeted lung cancer pill.

Benjamin Solomon led the PROFILE 1014 and CROWN trials that established crizotinib and then lorlatinib for ALK-positive NSCLC, and directs thoracic medical oncology and lung cancer research at Peter Mac.

Role
Professor of Medical Oncology; Head, Lung Medical Oncology, Peter Mac
Specialisms
Lung cancerALK inhibitorsTargeted therapyClinical trials

Papers

1top
TitleJournalYear
Lorlatinib versus crizotinib in patients with advanced ALK-positive NSCLC: 5-year outcomes from CROWNJournal of Clinical Oncology2024

Key papers

1top
rctNew England Journal of Medicine 2020changed practice
CROWN: lorlatinib versus crizotinib as first treatment for ALK-positive lung cancer

For ALK-positive advanced lung cancer, lorlatinib as the first drug offers the possibility of many years without progression and strong protection against brain metastases. Alectinib and brigatinib remain alternatives with a gentler side-effect profile; the choice weighs lorlatinib's cognitive, metabolic and weight effects against its unmatched duration of control.

Connected

7top

cancers

1
Non-small-cell lung cancer

targets

1
ALK

drugs

1
ApprovedSmall-molecule kinase inhibitor (ALK/ROS1)
Lorlatinib · Lorbrena

institutions

2
International Association for the Study of Lung CancerPeter MacCallum Cancer Centre

trials

1
CROWN

key papers

1
CROWN: lorlatinib versus crizotinib as first treatment for ALK-positive lung cancer